Source: European Journal of Pharmaceutical Sciences. Unidades: IME, FCF
Subjects: BIOEQUIVALÊNCIA, ANÁLISE DE SÉRIES TEMPORAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SOARES, Kelen Carine Costa e CHIANN, Chang e STORPIRTIS, Silvia. Assessment of the impact of partial area under the curve in a bioavailability/bioequivalence study on generic prolonged-release formulations. European Journal of Pharmaceutical Sciences, v. 171, n. artigo 106127, p. 1-6, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.ejps.2022.106127. Acesso em: 05 nov. 2024.APA
Soares, K. C. C., Chiann, C., & Storpirtis, S. (2022). Assessment of the impact of partial area under the curve in a bioavailability/bioequivalence study on generic prolonged-release formulations. European Journal of Pharmaceutical Sciences, 171( artigo 106127), 1-6. doi:10.1016/j.ejps.2022.106127NLM
Soares KCC, Chiann C, Storpirtis S. Assessment of the impact of partial area under the curve in a bioavailability/bioequivalence study on generic prolonged-release formulations [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 171( artigo 106127): 1-6.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.ejps.2022.106127Vancouver
Soares KCC, Chiann C, Storpirtis S. Assessment of the impact of partial area under the curve in a bioavailability/bioequivalence study on generic prolonged-release formulations [Internet]. European Journal of Pharmaceutical Sciences. 2022 ; 171( artigo 106127): 1-6.[citado 2024 nov. 05 ] Available from: https://doi.org/10.1016/j.ejps.2022.106127